K-RAS mutations appear in 25% of adenocarcinomas and may be a promising target of new therapeutic strategies (Sunaga et al, 2011), as well as the recently described EML4 protein (Radtke et al, 2010) and its EML4-ALK oncoprotein counterpart (Gerber and Minna, 2010). This evidence concerns the gene ALK and adenocarcinoma.